Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665273 · ClinicalTrials.gov registry record · Phase 3
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
A Phase 3 study of Migraine, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02665273: Completed Phase 3 study of Migraine, sponsored by Montefiore Medical Center.
NCT02665273 is a Phase 3 study of Migraine that has completed, run by Montefiore Medical Center. The registered enrollment target is 28 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02665273, a Phase 3 study of Migraine, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.
Primary Outcome
Pain assessed using a standard ordinal headache intensity scale, in which subjects describe their headache as "severe", "moderate", "mild", or "none". Those with headache level = none, experience freedom from headache.
Conditions Studied
Interventions
- DRUG Bupivacaine
- PROCEDURE Greater occipital nerve block
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
What the finished NCT02665273 record still lists
NCT02665273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine is the first listed.
NCT02665273 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02665273 about?
NCT02665273 is a clinical study titled "Greater Occipital Nerve Block With Bupivacaine for Acute Migraine". This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.
What is the current status of trial NCT02665273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2015-07-01. Estimated completion is 2018-01.
What conditions does trial NCT02665273 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT02665273?
The interventions under investigation include: Bupivacaine (DRUG), Greater occipital nerve block (PROCEDURE).
Who is sponsoring clinical trial NCT02665273?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02665273 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02665273's enrollment target sits among peer trials
28 96th of 102 higher than 7 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI